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Effect of furosemide on free water excretion in edematous
patients with hyponatremia. The present study was undertaken to
examine the effect of intravenous furosemide on urinary dilution
in patients with hyponatremia associated with edema formation
due to congestive heart failure, hepatic cirrhosis or nephrotic
syndrome. Despite the evidence that a major tubular effect of
furosemide is to inhibit sodium reabsorption in loops of Henle
where urinary dilution occurs, administration of the diuretic
resulted in a net increase in free water excretion in 4 of these 7
patients. This improved ability to excrete dilute urine occurred
in the absence of volume expansion and was not abolished by
infusing vasopressin. We conclude that the diuretic improved the
excretion of water as a result of incomplete osmotic equilibration
during high rates of flow through collecting ducts. Also, since
furosemide may interfere with proximal tubular reabsorption,
the diuretic could result in a net increase in the volume of dilute
tubular fluid generated as a result of increased delivery of tubular
fluid to diluting sites unaffected by the drug.
Effets de Ia furosémide sur l'excrétion d'eau fibre chez les
malades ayant des oedèmes et une hyponatrémie. Ce travail a été
entrepris pour examiner l'effet de Ia furosémide intraveineuse sur
la dilution urinaire chez des malades ayant une hyponatrémie
associée a des oedèmes dus a une insuffisance cardiaque con-
gestive, une cirrhose hépatique ou un syndrome néphrotique.
Malgré Ic fait evident que l'action tubulaire principale de la
furosémide est d'inhiber Ia reabsorption du sodium dans l'anse
de Henle oü Ia dilution urinaire est produite, l'administration de
diuretique a eu pour consequence une augmentation franche de
l'excrétion d'eau libre chez 4 des 7 malades. Cette amelioration
de Ia capacité d'excréter une urine diluée a été observée en
l'absence d'expansion et n'a pas été abolie par Ia vasopressine.
Nous concluons que le diurétique a amélioré l'excrétion de l'eau
du fait d'une equilibration osmotique incomplete pendant que
des debits élevés passaient dans les canaux collecteurs. De plus,
du fait que la furosémide peut interferer avec la reabsorption
proximale, le diurétique peut avoir augmenté Ia generation de
liquide tubulaire dilué par l'intermédiaire d'un debit accru de
liquide tubulaire aux zones de dilution non affectées par la
drogue.
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The administration of diuretic agents known to interfere
with distal tubular sodium reabsorption may reduce the
capacity to excrete dilute urine and lead to hyponatremia
in the presence of continued ingestion of water [1—3].
Spontaneous hyponatremia due to impaired capacity to
excrete dilute urine is frequently observed in patients with
avid retention of sodium due to heart failure, cirrhosis or
nephrotic syndrome. Nevertheless, these patients generally
are treated with diuretics such as furosemide which are
known to reduce urinary diluting capacity under other
circumstances [4]. It is a frequent clinical observation that
hyponatremia may appear, or become more severe, during
the course of such therapy. It is not unreasonable to
suppose that an agent such as furosemide, by its action to
block sodium transport in the ioop of Henle, intensifies any
existing limitation on diluting capacity and thereby pro-
motes further retention of water and increases the severity
of hyponatremia. However, furosemide, as well as etha-
crynic acid and the thiazides, limit but do not abolish the
ability to excrete dilute urine [4—6]. The limited capacity to
excrete dilute urine in patients with edema-forming diseases
and hyponatremia may be due, in part, to limited delivery
of tubular fluid to distal tubular diluting sites [7, 8]. There-
fore, it is conceivable that these diuretic drugs could have
the net effect of improving the ability to excrete "free water"
as a consequence of increased delivery of tubular fluid to
diluting sites where the diuretic does not block sodium
reabsorption. If so, the appearance or intensification of
hyponatremia in patients receiving these diuretics may be a
secondary and indirect effect of diuresis rather than a
consequence of the agent's direct impairment of diluting
capacity.
For these reasons patients with sodium letention, im-
paired excretion of water and hyponatremia were given
furosemide and the effects on urinary diluting ability were
studied acutely. In each patient there was a relative increase
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in free water excretion with the excretion of distinctly
hypotonic urine by some. Thus, the acute effect of this
diuretic agent was to increase the ability of these patients to
excrete water, an action that would serve to improve rather
than intensify hyponatremia.
Methods
Patients with heart disease, liver disease or nephrotic
syndrome were selected for the study on the basis of ex-
hibiting peripheral edema, a serum sodium concentation
below 135 mEq/liter and the excretion of concentrated urine
(ratio of urine to plasma osmolality greater than 1.0).
Patients i(s), 4(L), 5(X) and 7(LI1) had congestive heart
failure, patients 3(A) and 6(.) had hepatic cirrhosis and
patient 2(o) had lipoid nephrosis. The presence of hypo-
natremia and concentrated urine was demonstrated on more
than one occasion prior to including the patient in the
study. The study was approved by the Human Experimen-
tation Committee of the Academic Senate of the University
of California, San Francisco, and the patients gave their
signed consent to participate in the study.
Studies lasted six to seven hr during which time the
patients remained in the supine position except while
standing to void. Small amounts of water but no food were
allowed during the study. The protocol was as follows1:
at 8:00 a. m. an infusion containing both dextrose and
mannitol at concentrations of 5 g/l00 ml and inulin and
para-aminohippurate (PAH) in sufficient concentrations to
allow clearance measurements was started at 2 mI/mm and
continued throughout the study. One hour was allowed for
equilibration of clearance substances prior to commencing
1 One exception was patient 2 who received an acute (20 mI/kg)
oral water load prior to the diuretic study.
the experiment. After the patient emptied his bladder, three
20 mm control urine collections were made by spontaneous
voiding (three patients) or from indwelling urinary catheters
(four patients). Blood samples were collected through an
indwelling venous catheter at the midpoint of each clearance
period. After the three control periods, furosemide (1 mg/
kg) was injected intravenously and then infused at a rate of
1 mg/kg/hr. Twenty mm after starting the infusion of
furosemide, eight twenty mm urine collection periods were
made. Prior to the last four of these collections, five patients
were given 100 mU of vasopressin (Pitressin ®, Parke-Davis)
subcutaneously (two patients) or intravenously (three pa-
tients). Blood pressure and pulse were recorded every 15
mm throughout the studies. Urine and plasma samples
were analyzed for inulin, PAH, sodium, potassium and
osmolality. Analytical procedures and calculations have
been described previously [9].
Results
During the administration of furosemide there were no
consistent changes in arterial pressure or pulse rate in any
of the patients. The effects of the drug on renal hemody-
namics were variable (Table 1). In the six patients in whom
GFR (clearance of inulin) and CPAH were measured, these
values increased in three during the administration of
furosemide. In all seven patients a profound diuresis oc-
curred during administration of the diuretic. Mean urine
flow increased from 1.2±0.5 to 9.8 2.9 mI/mm (P <0.02)
and osmolar clearance (Csm) increased from 1.8 0.4 to
8.9 2.4 ml/min (P <0.02).
Prior to the administration of furosemide urinary sodium
concentration was below 4 mEq/liter and urinary potassium
concentration was greater than 20 mEq/liter in all seven
patients. Mean urinary sodium concentration increased
Tabie 1. Effect of furosemide on renal hemodynamics and solute excretion a, b
Patient V GFR CPAH Osmolality Cøsm Plasma Na
(urine/plasma)
mi/mm mi/mm mi/mm mOsrn/kg mi/rn in mEq/Iiter
control furo- control furo- control furo- control furo- control furo- control furo-
semide semide semide semide semide seniide
1 10 27 46 129 0.3 3.6 395/267 229/265 0.4 3.0 131 130
2 64 60 1061 1065 4.2 20.7 207/268 216/269 3.2 16.7 119 119
3 7 15 105 144 0.6 11.3 601/273 266/271 1.4 11.1 128 127
4 32 92 75 254 1.0 19.5 635/273 246/275 2.3 17.5 131 134
5 72 61 232 219 0.9 7.3 745/287 310/289 2.3 7.7 130 129
6 7 9 57 88 2.2 3.1 517/273 253/274 0.6 2.3 128 128
7 — — — — 1.0 4.2 584/252 236/252 2.3 3.8 126 126
Mean 32 44 262 317 1.2 9.8 526/271 251/271 1.8 8.9 128 128
±SEM ±12 ±13 ±162 ±152 ±0.5 ±2.9 ±721±4 ±131±5 ±0.4 ±2.4 ±2 ±2P NS NS <0.02 <0.02/NS <0.02 NS
a Abbreviations: V = rate of flow of urine; GFR =glomerular filtration rate (clearance of inulin); CPAH = clearance of p-amino-
hippurate; Cøsm= osmolar clearance (UøsmV/Pøsm).
b Values are the means of 3 to 4 consecutive collections.
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Fig. 1. Effect of furosemide on free water clearance (CH2O).
Each pair of points represents a single patient and is the mean
of 3 to 5 consecutive clearance periods.
from 2.1 to 71.5 9.3 mEq/liter (P <0.001) and mean
urinary potassium concentration decreased from 77±9.1
to 31 3.8 mEq/Iiter (P <0.01). The rate of sodium ex-
cretion increased from 1.8 to 763 jiEq/min
(P <0.05) as urinary potassium excretion increased from
77±23 to 268 jiEq/min (P <0.02).
In five patients, distinctly hypotonic urine was excreted
during infusion of furosemide and in the remaining two
patients urinary osmolality decreased to or near isotonicity
(Table 1). Mean urinary osmolality (Uosm) was 526 mOsm/
kg H20 before and 251 mOsm/kg H20 after the admini-
stration of furosemide (P <0.005). Mean CH2O increased
from —1.3 to + 0.45 mi/mm (P <0.02) and in two patients
(two and four, C1120 reached values of 2 and 4 mI/mm,
respectively (Fig. 1). Only one of the seven patients con-
tinued to have slightly negative CH2O during infusion of
furosemide. Five patients received exogenous vasopressin
during the last four periods of the study. There was no effect
of vasopressin to increase Uosm or decrease C1120 during
the furosemide-induced diuresis (Fig. 2).
Discussion
Despite the fact that furosemide appears to interfere
with sodium transport at tubular diluting sites [4, 10], the
Fig. 2. Effect of exogenous vasopressin on urinary osmolality and
free water clearance during furosemide-induced diuresis. Symbols
represent the same patients shown in Fig. 1. Values are the means
of 3 to 4 consecutive clearance periods before and after intra-
venous or subcutaneous administration of vasopressin (ADH).
drug actually brought about the excretion of dilute urine in
five of the seven patients studied here. In the remaining two
patients negative free water excretion (T20) approached
zero, so in these patients also there was relative improve-
ment in the ability to excrete solute-free water. Thus, it
seems unlikely that water retention and hyponatremia in
such patients receiving this diuretic agent can be attributed
directly to a tubular effect of the drug to impair diluting
capacity further. In fact, to the extent that furosemide may
increase the excretion of free water as observed in the
present study, the agent may serve directly to correct hypo-
natremia. It should be emphasized that secondary effects of
diuresis, such as more avid retention of sodium or an in-
creased release of vasopressin, may promote water retention
and intensify hyponatremia after the tubular effects of the
drug have subsided. We are not suggesting that the agent
is necessarily useful in treating hyponatremia in this group
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of patients, but simply that we found no evidence that the
tubular effects of the agent directly intensify the already
limited ability to excrete solute-free water.
The observation that furosemide abolished concentrating
ability and T20 in these patients is not surprising con-
sidering what is known about the renal effects of the drug
[10—12]. This could be due either to extensive interference
with sodium reabsorption in the medullary portion of the
ascending limb of Henle's loop [10, 11], to an increase in
medullary blood flow (if furosemide has such an effect), or
to delivery of large volumes of tubular fluid to collecting
ducts [12]. These changes, either alone or in combination,
could abolish medullary hypertonicity with the result that
the final urine would become isotonic. What perhaps is
more surprising are the observations that there was an
absolute increase in free water excretion in five patients,
three of whom were excreting concentrated urine prior to
administering furosemide. This occurred in the presence of
an assumed effect of the diuretic to interfere with sodium
reabsorption in diluting segments of the tubule.
There are several possible explanations for the excretion
of solute-free water during administration of furosemide to
patients who otherwise may not be able to excrete dilute
urine. It has been demonstrated before that the excretion of
free water may increase in such patients during solute
diuresis produced by infusion of mannitol [7, 8]. It was
suggested previously that this effect may be due to im-
proved delivery of tubular fluid to distal tubular diluting
sites, permitting increased formation of solute-free water
[7, 8]. It is implicit in this interpretation that the release of
vasopressin is already suppressed, presumably as a conse-
quence of the associated hyponatremia. Moreover, in these
previous studies the patients were volume expanded by the
infusions employed and this could have provided an addi-
tional stimulus for suppressing the release of vasopressin
[13], favoring the excretion of dilute urine. In the present
patients the improved ability to excrete dilute urine during
administration of furosemide occurred in the absence of
volume expansion (urinary losses induced by the diuretic
were not replaced) and in the presence of administration of
vasopressin. The latter observation is consistent with the
view that dilute urine was being excreted during furosemide
administration (in five of the patients) despite a maximal
renal effect of endogenous vasopressin.
It appears most likely that the excretion of dilute urine in
these patients was due to an effect of solute diuresis to
increase flow through collecting ducts and limit the extent
of osmotic equilibration of collecting duct fluid with the
surrounding medullary interstitium [12]. Even in the pre-
sence of maximal tubular effects of vasopressin, distal
tubular fluid remains hypotonic in the dog [11] and monkey
[14]. At high rates of solute excretion dilute urine may be
excreted by the dog [15] and monkey [16], despite the
presence of vasopressin; the same phenomenon may occur
in man under some conditions [17, 18]. Presumably, in the
presence of solute diuresis hypotonic distal tubular fluid is
delivered through collecting ducts at rates so high that
passive equilibration, even to isotonicity, cannot occur.
Since the increased excretion of water in the present patients
was unresponsive to vasopressin we assume that this effect
was occurring. In addition, it seems possible that the diuretic
may actually increase the amount of dilute tubular fluid
generated, as a consequence of inhibition of proximal tubu-
lar reabsorption [19] and increased delivery of tubular fluid
to diluting segments not affected by the drug [4, 10].
Acknowledgements
These studies were supported by a grant from Hoechst
Pharmaceutical Company; grants AM 12753, HE 13319-01
and AM 05670-02 from the National Institutes of Health,
and NGR-05-025-007 from the National Aeronautics and
Space Administration. Some of these studies were carried
out in the General Clinical Research Center, provided by
the Division of Research Facilities and Resources under a
grant (PHS FR-79) from the U. S. Public Health Service.
The authors are grateful to Lisbeth Streiff and Judith
Harbottle for their technical assistance and to Mrs. Vicki
Wagner for secretarial assistance.
Reprint requests to Dr. Laurence E. Earley, University of
California San Francisco, 3rd and Parnassus Avenue, Room 1080
HSE, San Francisco, California 94122, U.S.A.
References
1. FICHMAN MP, VORHERR H, KLEEMAN CR, TELFER N: Diure-
tic-induced hyponatremia. Ann mt Med 75:853—863, 1971
2. KENNEDY RM, EARLEY LE: Profound hyponatremia result-
ing from a thiazide-induced decrease in urinary diluting
capacity in a patient with primary polydipsia. New Engi J
Med 282:1185—1186, 1970
3. BERESFORD HR: Polydipsia, hydrochlorothiazide, and water
intoxication. JAMA 214:879—883, 1970
4. SELDIN DW, EKNOYAN G, SuKI WN, RECTOR JR, FC: Lo-
calization of diuretic action from the pattern of water and
electrolyte excretion. Ann NY Acad Sci 139:328—343, 1966
5. EARLEY LE, ORLOFF J: The mechanism of antidiuresis asso-
ciated with the administration of hydrochiorothiazide to
patients with vasopressin-resistant diabetes insipidus. J C/in
Invest 41:1988—1997, 1962
6. EARLEY LE, FRIEDLER RM: Renal tubular effects of etha-
crynic acid. J C/in Invest 43:1495, 1506, 1964
7. SCI-IEDL HP, BARTTER FC: An explanation for and experi-
mental correction of the abnormal water diuresis in cirrhosis.
J C/in Invest 29:248—261, 1960
8. BELL NH, SCHEDL HP, BARTTER FC: An explanation for
abnormal water retention and hypoosmolality in congestive
heart failure. Am J Med 36:351—360, 1964
9. SCHRIER RW, EARLEY LE: Effects of hematocrit on renal
hemodynamics and sodium excretion in hydropenic and
volume-expanded dogs. J C/in Invest 49:1656—1667, 1970
10. CLAPP JR. ROBINSON RR: Distal sites of action of diuretic
drugs in the dog nephron. Am J Physiol 215:228—235. 1968
34 Schrier et a!
11. Hooic JB, WILLIAMSON HE: Effect of furosemide on renal
medullary sodium gradient. Proc Soc Exp Biol and Med
118:372—374, 1965
12. ORLOFF J, WAGNER JR, HN, DAVIDSON DG: The effects of
variations in solute excretion and vasopressin dosage on the
excretion of water in the dog. J C/in Invest 37:458—464, 1958
13. STRAUSS MB, BIRCHARD WH, SAXON L: Correction of im-
paired water excretion in cirrhosis of the liver by alcohol
ingestion or expansion of extracellular fluid volume: the role
of the antidiuretic hormone. Trans Assn Am Phys 49:222—
228, 1956
14. BENNETT CM, BRENNER BM, BERLINER RW: Micropuncture
study of nephron function in the rhesus monkey. J C/in In-
vest 47:203—216, 1968
15. WESSON LG, ANSLOW WP, RAISZ LG, BOLOMEY AA, LADD
M: Effect of sustained expansion of extracellular fluid
volume upon filtration rate, renal plasma flow and electro-
lyte and water excretion in the dog. Am J Physiol 162:
677—686, 1950
16. TISHER CC, SCHRIER RW, MCNEIL JS: Nature of the urine
concentrating mechanism in the macaque monkey. Am J
Physiol 223:1128—1137, 1972
17. TANNEN RL, REGAL EM, DUNN MJ, SCHRIER RW: Vaso-
pressin-resistant hyposthenuria in advanced chronic renal
disease. New EnglJMed28O:1135—1141, 1969
18. ZAK GA, BRUN C, SMITH HW: The mechanism of formation
of osmotically concentrated urine during the antidiuretic
state. J Clin Invest 33:1064—1074, 1954
19. BRENNER BM, KEIMOWITZ RI, WRIGHT FS, BERLINER RW:
An inhibitory effect of furosemide on sodium reabsorption by
the proximal tubule of the rat nephron. J C/in Invest 48:
290—300, 1969
